Controlling Blood Glucose Levels in Mice: A New Type 1 Diabetes Development
News Nov 18, 2013
Researchers in Belgium have successfully generated insulin-producing beta cells from other pancreatic cells in mice with type 1 diabetes. The mice were then able to control their own glucose levels without additional insulin.
The study, part-funded by JDRF, the type 1 diabetes charity, was published today in Nature Biotechnology.
In those living with the condition, the immune system attacks the beta cells of the pancreas, leaving the person unable to produce insulin. This means they cannot control their own blood glucose, and must rely on insulin injections to stay alive.
However, the other pancreatic cells remain functional, and reprogramming these to produce insulin is a potential pathway to treating the condition.
The researchers simulated type 1 diabetes in the mice and after five weeks, some of these mice received a course of proteins (epidermal growth factor and ciliary neurotrophic factor) that have been known to stimulate beta cell growth in the lab.
The treated mice subsequently began producing insulin, and their blood glucose levels fell to match those of mice with functioning beta cells. The other mice continued to experience hyperglycaemia (high blood glucose levels).
By tracing the genetic origin of the newly grown beta cells, the researchers found that they were mostly derived from another type of pancreatic cell, called acinar cells. These normally help the pancreas secrete digestive juices, and are not involved in insulin production.
Dr. Harry Heimberg, Principle Investigator from Diabetes Research Centre at the University of Brussels, said: “Acinar cells can be reprogrammed to beta-like cells in the laboratory. Several characteristics make acinar cells ideal candidates for reprogramming to beta cells in the pancreas as well: they are the most abundant cell type, their microenvironment is identical to that of beta cells and they are not affected by diabetes."
This study provides hope for those living with type 1 diabetes, but more research will be necessary to see if the findings can help those living with the condition, as it is likely that the immune system would still attack any newly-formed beta cells.
Dr Heimberg added: "We hope that our model will contribute to the development of a robust and safe strategy for beta cell therapy in diabetes."
Karen Addington, Chief Executive of JDRF, said: “The results from this study are interesting, and certainly appear deserving of further exploration. Type 1 diabetes is a challenging and complex condition. But it will one day be cured. It's just a matter of time, money and excellent research."
Tiny “Tornado” Boosts Performance of Electrospray Ionization Mass SpectrometryNews
Known as Dry Ion Localization and Locomotion (DRILL), the new device creates a swirling flow that can separate electrospray droplets depending on their size.READ MORE
Molecular Mechanism That Enable Neuronal Connections to Change With Development DiscoveredNews
Researchers from King's College London have discovered a molecular mechanism that enables neuronal connections to change through experience, thus fuelling learning and memory formation.READ MORE
Agilent Presents Early Career Professor Award to Dr. Gary PattiNews
Professor Gary Patti from Washington University earns the prestigious Early Career Professor Award for his work in Metabolomics.READ MORE
Comments | 0 ADD COMMENT
11th Edition of International Conference on Proteomics 2018
Mar 22 - Mar 23, 2018
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018